Buscar
Congreso SOLACI
HomeESC 2024Structural Heart Disease

Structural Heart Disease

Ver Categoría
Structural Heart Disease

ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women

The RHEIA trial is the first randomized, women-exclusive international study aimed to assess the safety and efficacy...
Dr. Omar Tupayachi -
Ver más
Antithrombotic Anticoagulants

ESC 2024 | POPular PAUSE TAVI: Continuation vs. Discontinuation of Oral Anticoagulant Therapy During TAVI

Due to their advanced age and comorbidities, many patients with severe aortic stenosis scheduled for transcatheter aortic...
Dr. Omar Tupayachi -
Ver más
Chronic Coronary Syndromes

ESC 2024 | NOTION 3 Trial: Percutaneous Coronary Intervention in Patients with a Planned Transcatheter Aortic Valve Implantation

The relationship between aortic stenosis and valve disease is well established, with revascularization rates in this population...
Dr. Omar Tupayachi -
Ver más
Other

ESC 2024 | TRI.Fr: Transcatheter Tricuspid Repair for the Treatment of Tricuspid Regurgitation

Right-sided heart failure and tricuspid regurgitation (TR) are associated with poor quality of life and an increased...
Dr. Omar Tupayachi -
Ver más
Mitral valve

ESC 2024 | MATERHORN Trial: Transcatheter vs. Surgical Mitral Repair in Patients with Heart Failure and Secondary Mitral Regurgitation

European guidelines consider transcatheter therapy as an alternative for patients with secondary mitral regurgitation who are not...
Dr. Omar Tupayachi -
Ver más
Mitral valve

ESC 2024 | RESHAPE-HF2: MitraClip in Heart Failure and Moderate to Severe Mitral Regurgitation

The aim of this study was to assess the effectiveness of MitraClip in patients with secondary mitral...
Dr. Omar Tupayachi -
Ver más
Other

ESC 2024 | STOP-or-NOT Trial: Optimal Management of Renin-Angiotensin System Inhibition Before Non-Cardiac Surgery

Researchers conducted a multicenter, randomized study to assess the continuation of renin-angiotensin system inhibition (RASI) before major...
Dr. Omar Tupayachi -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad